Figure 10.

(A) ⁶⁸Ga-PSMA-11 PET/CT scans of patient A. Pretherapeutic tumor spread (i), restaging 2 months after third cycle of ²²⁵Ac-PSMA-617 (ii), and restaging 2 months after one additional consolidation therapy (iii). (B) ⁶⁸Ga-PSMA-11 PET/CT scans of patient B. In comparison to initial tumor spread (i), restaging after 2 cycles of β-emitting ¹⁷⁷Lu-PSMA-617 presented progression (ii). In contrast, restaging after second (iii) and third (iv) cycles of ²²⁵Ac-PSMA-617 therapy presented impressive response. Adapted from Ref. [96] with permission. Copyright 2016 Society of Nuclear Medicine and Molecular Imaging.